. 2015 Oct;21(10).
doi: 10.1038/nm.3944.

Natural and therapy-induced immunosurveillance in breast cancer

Guido Kroemer 1 Laura Senovilla 1 Lorenzo Galluzzi 1 Fabrice André 2 Laurence Zitvogel 2 
  • PMID: 26444637
  •     90 citations


The immunosurveillance theory postulates that tumors evolve and progress in an uncontrolled fashion only when anticancer immune responses fail. Natural immunosurveillance clearly influences human breast cancer (BC) progression because the prognosis of BC patients is dictated by the density, composition and activity of the tumor immune infiltrate at diagnosis. Moreover, chemotherapeutic and radiotherapeutic regimens commonly employed for the treatment of BC affect the tumor immune infiltrate, and accumulating data suggest that the clinical efficacy of these treatments is largely determined by T cell-dependent tumor-specific immune responses. In addition, the mechanism of action of targeted anticancer therapeutics, such as the erb-b2 receptor tyrosine kinase 2 (ERBB2)-targeting agent trastuzumab, involves the innate and adaptive arms of the immune system. In this Review, we discuss these findings as well as preliminary evidence indicating that immunotherapy constitutes a promising option for the treatment of BC. Moreover, we point out that the successful implementation of immunotherapy to BC management requires the optimization of current immunotherapeutic regimens and the identification of immunological biomarkers that enable improved risk stratification and the design of personalized, dynamic treatment plans.

Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.
Rashmi Verma, Ruth E Foster, +5 authors, Clive R D Carter.
Breast Cancer Res, 2016 Jan 27; 18(1). PMID: 26810608    Free PMC article.
The oncolytic peptide LTX-315 triggers immunogenic cell death.
H Zhou, S Forveille, +11 authors, G Kroemer.
Cell Death Dis, 2016 Mar 11; 7. PMID: 26962684    Free PMC article.
The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.
Sylvain Ladoire, David Enot, +13 authors, Guido Kroemer.
Autophagy, 2016 Mar 17; 12(5). PMID: 26979828    Free PMC article.
Highly Cited.
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.
Carly Bess Williams, Elizabeth S Yeh, Adam C Soloff.
NPJ Breast Cancer, 2016 Mar 22; 2. PMID: 26998515    Free PMC article.
Highly Cited.
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection.
Vikram Mehraj, Mohammad-Ali Jenabian, +9 authors, Montreal Primary HIV Infection, the Canadian Long-Term Non-Progressors Study Groups.
AIDS, 2016 Apr 06; 30(10). PMID: 27045377    Free PMC article.
Trial Watch-Immunostimulation with cytokines in cancer therapy.
Erika Vacchelli, Fernando Aranda, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057468    Free PMC article.
Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.
Bo Liu, Yanfeng Tian, +5 authors, Like Zhang.
Oncol Rep, 2016 Apr 26; 35(6). PMID: 27109339    Free PMC article.
Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wei Xiong Wen, Jaslyn Sian-Siu Soo, +9 authors, Soo Hwang Teo.
Breast Cancer Res, 2016 May 29; 18(1). PMID: 27233495    Free PMC article.
Immunological Mechanisms in Breast Cancer - from Bench to Bedside.
Carsten Denkert, Florian Schütz.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239169    Free PMC article.
Prevention of breast cancer by RANKL/RANK blockade.
Lorenzo Galluzzi, Aitziber Buqué, Guido Kroemer.
Cell Res, 2016 Jun 22; 26(7). PMID: 27325297    Free PMC article.
Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1.
Erika Vacchelli, Yuting Ma, +2 authors, Guido Kroemer.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467929    Free PMC article.
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
Aitziber Buqué, Norma Bloy, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471617    Free PMC article.
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.
Sylvain Ladoire, Laura Senovilla, +9 authors, Guido Kroemer.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471635    Free PMC article.
Positive impact of autophagy in human breast cancer cells on local immunosurveillance.
Sylvain Ladoire, David Enot, +3 authors, Guido Kroemer.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471653    Free PMC article.
Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.
In Ah Park, Sun-Hee Heo, +7 authors, Gyungyub Gong.
Oncotarget, 2016 Aug 06; 7(37). PMID: 27494867    Free PMC article.
Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity.
Rebecca Posselt, Katharina Erlenbach-Wünsch, +7 authors, Luitpold V Distel.
Oncotarget, 2016 Aug 06; 7(37). PMID: 27494875    Free PMC article.
Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.
Jason R Todd, Karen A Ryall, +5 authors, Paul H Huang.
Oncotarget, 2016 Aug 25; 7(39). PMID: 27556857    Free PMC article.
The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.
Ling Wang, Fu-Biao Kang, +4 authors, Bao-En Shan.
Tumour Biol, 2016 Sep 21; 37(11). PMID: 27644254
Emerging roles of p53 and other tumour-suppressor genes in immune regulation.
César Muñoz-Fontela, Anna Mandinova, Stuart A Aaronson, Sam W Lee.
Nat Rev Immunol, 2016 Nov 01; 16(12). PMID: 27667712    Free PMC article.
Highly Cited. Review.
Mouse models in oncoimmunology.
Laurence Zitvogel, Jonathan M Pitt, +2 authors, Guido Kroemer.
Nat Rev Cancer, 2016 Nov 04; 16(12). PMID: 27687979
Highly Cited. Review.
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.
Jitka Fucikova, Iva Truxova, +12 authors, Radek Spisek.
Blood, 2016 Nov 03; 128(26). PMID: 27802968    Free PMC article.
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).
Anja K Wege, Florian Weber, +3 authors, Gero Brockhoff.
Oncotarget, 2016 Nov 12; 8(2). PMID: 27835865    Free PMC article.
The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.
Michaela Semeraro, Julien Adam, +15 authors, Guido Kroemer.
Oncoimmunology, 2016 Nov 18; 5(10). PMID: 27853639    Free PMC article.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Stephen J Luen, Roberto Salgado, +8 authors, Sherene Loi.
Lancet Oncol, 2016 Dec 15; 18(1). PMID: 27964843    Free PMC article.
Highly Cited.
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.
Jon Amund Kyte, Steinar Aamdal, +6 authors, Gunnar Kvalheim.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999747    Free PMC article.
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.
Noelia Purroy, Catherine J Wu.
Cold Spring Harb Perspect Med, 2017 Jan 18; 7(4). PMID: 28096240    Free PMC article.
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.
Jaime A Espinoza, Shakila Jabeen, +10 authors, Irina Gromova.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123884    Free PMC article.
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.
Melissa Bersanelli, Sebastiano Buti.
World J Clin Oncol, 2017 Mar 02; 8(1). PMID: 28246584    Free PMC article.
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.
Kristin G Anderson, Ingunn M Stromnes, Philip D Greenberg.
Cancer Cell, 2017 Mar 16; 31(3). PMID: 28292435    Free PMC article.
Highly Cited. Review.
Pro-necrotic molecules impact local immunosurveillance in human breast cancer.
Gautier Stoll, Yuting Ma, +3 authors, Guido Kroemer.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507808    Free PMC article.
Autophagy in natural and therapy-driven anticancer immunosurveillance.
Federico Pietrocola, José Manuel Bravo-San Pedro, Lorenzo Galluzzi, Guido Kroemer.
Autophagy, 2017 Jun 10; 13(12). PMID: 28598229    Free PMC article.
An epigenetic modifier triggers therapeutic immune responses against breast cancer.
Lorenzo Galluzzi, Guido Kroemer.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638742    Free PMC article.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens.
Clin Cancer Res, 2017 Aug 13; 24(3). PMID: 28801472    Free PMC article.
Highly Cited. Review.
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Lironne Wein, Peter Savas, +3 authors, Sherene Loi.
Front Oncol, 2017 Aug 22; 7. PMID: 28824872    Free PMC article.
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Gloria Romagnoli, Meike Wiedermann, +6 authors, Ibrahim Alkatout.
Int J Mol Sci, 2017 Sep 09; 18(9). PMID: 28885584    Free PMC article.
Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
Fatemeh Vahedi, Tina Nham, +4 authors, Ali A Ashkar.
Sci Rep, 2017 Sep 25; 7(1). PMID: 28935883    Free PMC article.
Identification of pharmacological agents that induce HMGB1 release.
Peng Liu, Liwei Zhao, +11 authors, Guido Kroemer.
Sci Rep, 2017 Nov 04; 7(1). PMID: 29097772    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Mitochondrial metabolism and cancer.
Paolo Ettore Porporato, Nicoletta Filigheddu, +2 authors, Lorenzo Galluzzi.
Cell Res, 2017 Dec 09; 28(3). PMID: 29219147    Free PMC article.
Highly Cited. Review.
The Amide Local Anesthetic Lidocaine in Cancer Surgery-Potential Antimetastatic Effects and Preservation of Immune Cell Function? A Narrative Review.
Thiên-Nga Chamaraux-Tran, Tobias Piegeler.
Front Med (Lausanne), 2018 Jan 13; 4. PMID: 29326939    Free PMC article.
Lysosome-targeting agents in cancer therapy.
Guido Kroemer, Lorenzo Galluzzi.
Oncotarget, 2018 Jan 20; 8(68). PMID: 29348815    Free PMC article.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.
Yuanqin Yin, Jingjing Cai, +2 authors, Youhong Jiang.
Cancer biology & therapy, 2018 Mar 22; 19(4). PMID: 29561704    Free PMC article.
Mechanisms of immune evasion in breast cancer.
Joshua P Bates, Roshanak Derakhshandeh, Laundette Jones, Tonya J Webb.
BMC Cancer, 2018 May 13; 18(1). PMID: 29751789    Free PMC article.
Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes.
Karin Zins, Gerwin Heller, +2 authors, Dietmar Abraham.
Oncotarget, 2018 May 26; 9(33). PMID: 29796177    Free PMC article.
Epigenetic anticancer agents cause HMGB1 release in vivo.
Peng Liu, Liwei Zhao, +3 authors, Guido Kroemer.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872561    Free PMC article.
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
Elena García-Martínez, Melody Smith, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872569    Free PMC article.
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Yunfei Zhao, Jiao He, +2 authors, Zhi Liu.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963106    Free PMC article.
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
Gemma A Foulds, Jayakumar Vadakekolathu, +9 authors, Stephanie E B McArdle.
Front Immunol, 2018 Sep 27; 9. PMID: 30254632    Free PMC article.
Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts.
Gautier Stoll, Jonathan Pol, +2 authors, Guido Kroemer.
Oncoimmunology, 2018 Oct 06; 7(10). PMID: 30288345    Free PMC article.
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Kazuhiro Araki, Yoshinori Ito, +9 authors, Yasuo Miyoshi.
BMC Cancer, 2018 Oct 18; 18(1). PMID: 30326862    Free PMC article.
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Jianqin Lu, Xiangsheng Liu, +6 authors, Andre E Nel.
ACS Nano, 2018 Nov 30; 12(11). PMID: 30481959    Free PMC article.
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate.
Lorenzo Galluzzi, Guido Kroemer.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524910    Free PMC article.
Trial watch: Peptide-based vaccines in anticancer therapy.
Lucillia Bezu, Oliver Kepp, +6 authors, Lorenzo Galluzzi.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524907    Free PMC article.
Highly Cited. Review.
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
Iva Truxova, Lenka Kasikova, +17 authors, Jitka Fucikova.
J Immunother Cancer, 2018 Dec 12; 6(1). PMID: 30526667    Free PMC article.
Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy.
Francesca Castoldi, Erika Vacchelli, +3 authors, Guido Kroemer.
Oncoimmunology, 2018 Dec 14; 8(1). PMID: 30546941    Free PMC article.
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.
Tiziana Triulzi, Luca Forte, +6 authors, Elda Tagliabue.
Oncoimmunology, 2018 Dec 14; 8(1). PMID: 30546951    Free PMC article.
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Wei Xie, Sabrina Forveille, +9 authors, Oliver Kepp.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646106    Free PMC article.
A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.
Sarah Lévesque, Julie Le Naour, +12 authors, Jonathan G Pol.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646107    Free PMC article.
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
Wenda Ye, Sreenivasulu Gunti, +4 authors, Nicole C Schmitt.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002309    Free PMC article.
Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Jung-Won Choi, Eui Soo Lee, +5 authors, Seahyoung Lee.
BMC Cancer, 2019 Aug 21; 19(1). PMID: 31426763    Free PMC article.
Checkpoint blockade in the treatment of breast cancer: current status and future directions.
Lironne Wein, Stephen J Luen, +2 authors, Sherene Loi.
Br J Cancer, 2018 May 29; 119(1). PMID: 29808015    Free PMC article.
IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.
Heather M Gibson, Brooke N McKnight, +6 authors, Nerissa T Viola-Villegas.
Cancer Res, 2018 Aug 18; 78(19). PMID: 30115693    Free PMC article.
The Interferon-Gamma Paradox in Cancer.
M Raza Zaidi.
J Interferon Cytokine Res, 2018 Nov 06; 39(1). PMID: 30388040    Free PMC article.
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.
Tiziana Triulzi, Viola Regondi, +8 authors, Elda Tagliabue.
Br J Cancer, 2018 Nov 28; 119(12). PMID: 30478407    Free PMC article.
Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Kang Wang, Hai-Lin Li, +5 authors, Hong-Yuan Li.
Cancer Med, 2019 Jan 25; 8(2). PMID: 30677255    Free PMC article.
Recent advances in triple negative breast cancer: the immunotherapy era.
Antonio Marra, Giulia Viale, Giuseppe Curigliano.
BMC Med, 2019 May 10; 17(1). PMID: 31068190    Free PMC article.
Highly Cited. Review.
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
So-Jin Park, Wenda Ye, +5 authors, Nicole C Schmitt.
Oral Oncol, 2019 Jul 28; 95. PMID: 31345380    Free PMC article.
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.
Ellen Brenner, Barbara F Schörg, +32 authors, Martin Röcken.
Nat Commun, 2020 Mar 14; 11(1). PMID: 32165639    Free PMC article.
Metabolic enzymes expressed by cancer cells impact the immune infiltrate.
Gautier Stoll, Margerie Kremer, +7 authors, Guido Kroemer.
Oncoimmunology, 2019 May 10; 8(6). PMID: 31069148    Free PMC article.
Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Milim Kim, Yul Ri Chung, +3 authors, So Yeon Park.
Breast Cancer Res, 2020 Mar 29; 22(1). PMID: 32216826    Free PMC article.
Outcomes and prognostic factors for women with breast cancer in Malawi.
Victoria M Youngblood, Ruth Nyirenda, +19 authors, Tamiwe Tomoka.
Cancer Causes Control, 2020 Mar 04; 31(4). PMID: 32124187    Free PMC article.
Immune Escape during Breast Tumor Progression.
Carlos R Gil Del Alcazar, Maša Alečković, Kornelia Polyak.
Cancer Immunol Res, 2020 Apr 03; 8(4). PMID: 32238387    Free PMC article.
HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Atefeh Arab, Rezvan Yazdian-Robati, Javad Behravan.
Arch Immunol Ther Exp (Warsz), 2020 Jan 10; 68(1). PMID: 31915932    Free PMC article.
Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties.
Martha Baydoun, Olivier Moralès, +11 authors, Nadira Delhem.
J Clin Med, 2020 Apr 25; 9(4). PMID: 32326210    Free PMC article.
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Robert Wesolowski, Andrew Stiff, +19 authors, William E Carson.
BMC Cancer, 2020 May 21; 20(1). PMID: 32429929    Free PMC article.
Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer.
Shamir Cassim, Milica Vučetić, Maša Ždralević, Jacques Pouyssegur.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365833    Free PMC article.
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
J A Kyte, A Røssevold, R S Falk, B Naume.
J Transl Med, 2020 Jun 25; 18(1). PMID: 32576225    Free PMC article.
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.
J A Kyte, N K Andresen, +4 authors, B Naume.
J Transl Med, 2020 Jul 06; 18(1). PMID: 32620163    Free PMC article.
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.
Iva Truxova, Lenka Kasikova, +14 authors, Jitka Fucikova.
Haematologica, 2019 Oct 05; 105(7). PMID: 31582537    Free PMC article.
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Aitziber Buqué, Norma Bloy, +27 authors, Lorenzo Galluzzi.
Nat Commun, 2020 Aug 01; 11(1). PMID: 32732875    Free PMC article.
An unexpected link between immunogenic cell death and inhibition of gene transcription.
Juliette Humeau, Allan Sauvat, Oliver Kepp, Guido Kroemer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923155    Free PMC article.
NK cells beat T cells at early breast cancer control.
Aitziber Buque, Norma Bloy, +2 authors, Lorenzo Galluzzi.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923169    Free PMC article.
Trial watch: IDO inhibitors in cancer therapy.
Julie Le Naour, Lorenzo Galluzzi, +2 authors, Erika Vacchelli.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934882    Free PMC article.
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Helena Earl, Louise Hiller, +24 authors, Janet A Dunn.
Health Technol Assess, 2020 Sep 04; 24(40). PMID: 32880572    Free PMC article.
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
Pelagia G Tsoutsou, Khalil Zaman, +3 authors, Marie-Catherine Vozenin.
Front Oncol, 2019 Jan 09; 8. PMID: 30619749    Free PMC article.
Anticancer effects of anti-CD47 immunotherapy in vivo.
Kristina Iribarren, Aitziber Buque, +6 authors, Guido Kroemer.
Oncoimmunology, 2019 Feb 07; 8(3). PMID: 30723582    Free PMC article.
Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer.
Tong Lin, Yuqin Qiu, Wenya Peng, Lisheng Peng.
Biomed Res Int, 2020 Nov 05; 2020. PMID: 33145341    Free PMC article.
De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.
Samuel T Workenhe, Andrew Nguyen, +12 authors, Karen L Mossman.
Commun Biol, 2020 Nov 06; 3(1). PMID: 33149194    Free PMC article.